Logo

Innovent Reports NMPA Approval to the NDA for IBI351 & Grants Priority Review Designation

Share this
Innovent

Innovent Reports NMPA Approval to the NDA for IBI351 & Grants Priority Review Designation

Shots:

  • The NDA approval and Priority Review Designation were based on the P-II study (NCT05005234) evaluating the safety & efficacy of IBI351 monotx. on NSCLC patients (n=264) with KRAS G12C mutation & was intolerant to standard treatment
  • Previously, the P-I study data depicted an ORR of 61.2% & DCR of 92.5%, additionally, mDOR was not met yet, the 6-month DoR rate was 75.4% & patients treated with 600mg BID showed better efficacy with ORR of 66.7% & DCR of 96.7%. The median PFS was 8.2mos. & 6 & 9 mos. PFS rate was 58.9% & 47.3%
  • IBI351, a KRAS G12C inhibitor, works by covalently and permanently altering the cysteine residue of the KRAS G12C protein

Ref: Innovent  | Image: Innovent

Related News:- Innovent Entered into Clinical Trial Collaboration and Supply Agreement with Merck KGaA to Evaluate IBI351 + Erbitux (cetuximab) for KRASG12C-Mutated NSCLC in China

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions